Physician profile
Dogan H Temizer
NPI 1407847031
$425.65
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $155.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $54.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $52.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.49 | 2019 | |
| Abbott Laboratories | $29.97 | 2019 | |
| Amarin Pharma, INC. | $22.89 | 2019 | |
| Ge Healthcare | $15.54 | 2019 | |
| Portola Pharmaceuticals, LLC | $14.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.82 | 2019 | |
| Novo Nordisk INC | $12.59 | 2019 | |
| Pfizer INC. | $11.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $10.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dogan Temizer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.